---
title: "Moolec Science SA Regains Compliance with All Nasdaq Capital Market Continued Listing Requirements Within Panel Remediation Period | MLEC Stock News"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/286326028.md"
description: "Moolec Science SA Regains Compliance with All Nasdaq Capital Market Continued Listing Requirements Within Panel Remediation Period | MLEC Stock News"
datetime: "2026-05-13T14:35:38.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/286326028.md)
  - [en](https://longbridge.com/en/news/286326028.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/286326028.md)
---

# Moolec Science SA Regains Compliance with All Nasdaq Capital Market Continued Listing Requirements Within Panel Remediation Period | MLEC Stock News

Moolec Science SA Regains Compliance with All Nasdaq Capital Market Continued Listing Requirements Within Panel Remediation Period | MLEC Stock News

### Related Stocks

- [MLEC.US](https://longbridge.com/en/quote/MLEC.US.md)
- [BBH.US](https://longbridge.com/en/quote/BBH.US.md)
- [LABU.US](https://longbridge.com/en/quote/LABU.US.md)
- [PBE.US](https://longbridge.com/en/quote/PBE.US.md)
- [BIB.US](https://longbridge.com/en/quote/BIB.US.md)
- [IBB.US](https://longbridge.com/en/quote/IBB.US.md)
- [FBT.US](https://longbridge.com/en/quote/FBT.US.md)
- [SBIO.US](https://longbridge.com/en/quote/SBIO.US.md)
- [XBI.US](https://longbridge.com/en/quote/XBI.US.md)
- [MLECW.US](https://longbridge.com/en/quote/MLECW.US.md)

## Related News & Research

- [Full Transcript: Cellectar Biosciences Q1 2026 Earnings Call](https://longbridge.com/en/news/286422585.md)
- [Legend Biotech Q1 Solid for Carvykti, Focus Shifts to In Vivo Pipeline, RBC Says](https://longbridge.com/en/news/286290495.md)
- [Co-Diagnostics Advances Ebola Preparedness With New Bundibugyo Virus Assay Strategy; Stock Up](https://longbridge.com/en/news/286956797.md)
- [Genprex data shows gene therapy reverses hyperglycemia in T2D mice at ASGCT](https://longbridge.com/en/news/286414681.md)
- [Regenxbio's muscle disorder therapy meets main goal in late-stage study](https://longbridge.com/en/news/286406339.md)